What is it?
Semaglutide is a GLP-1 receptor agonist and the active ingredient in Wegovy and Ozempic.
A physician-directed approach to GLP-1 weight management—built around a real medical evaluation, individualized dosing, and ongoing follow-up.
A consultation does not guarantee a prescription. Eligible Florida patients may be seen by telemedicine.

Clear, medically grounded information before you decide whether a consultation makes sense.
Semaglutide is a GLP-1 receptor agonist and the active ingredient in Wegovy and Ozempic.
Yes. Every NovaGenix patient is evaluated and monitored by Timothy Mackey, D.O.
Semaglutide is administered as a once-weekly subcutaneous injection with gradual dose increases.
In STEP 1, participants receiving semaglutide plus lifestyle intervention lost 14.9% of starting weight on average at 68 weeks. Results vary.
Eligible patients throughout Florida may be seen by telemedicine when clinically appropriate.
No. Treatment is prescribed only after a medical evaluation confirms it is appropriate.
Semaglutide is the active ingredient in Wegovy and Ozempic. NovaGenix prescribes compounded semaglutide, which is prepared by a licensed compounding pharmacy and is not an FDA-approved finished drug product.
Your treatment is prescribed and monitored after a medical evaluation and review of your medications and health history. Semaglutide works by mimicking GLP-1, a naturally occurring hormone involved in appetite regulation.
Eligibility is based on more than a number on the scale. Medical history, current medications, goals, risks, and alternatives all matter.
A physician should review your health history, medications, prior weight-loss treatment, and potential contraindications before any decision is made.
Review important safety information →Semaglutide is a prescription medication—not a program you join by completing an online questionnaire.
Meet with Timothy Mackey, D.O., in Jupiter or by eligible Florida telehealth to review history, medications, and goals.
Laboratory testing is ordered case by case when an underlying thyroid, hormone, or metabolic issue may be relevant.
Treatment starts low and is increased gradually based on tolerability and clinical response.
Follow-up tracks progress, adjusts treatment where appropriate, and addresses side effects early.
Common side effects include nausea, diarrhea, vomiting, constipation, and abdominal discomfort. They are most likely during the first weeks of treatment and while the dose is being increased.
Anything severe or persistent should be reported promptly rather than waiting for the next scheduled visit.
Both are once-weekly injectable medications used for weight management, but they act on different pathways.
Acts on the GLP-1 receptor. The appropriate medication depends on your medical history, other medications, tolerability, cost, and availability.
Acts on both GLP-1 and GIP receptors. The choice is made during consultation—not before your medical evaluation.
Learn about tirzepatide →NovaGenix is a self-pay practice and does not bill insurance. There is no single program price because formulations, strengths, testing, and follow-up needs vary.
Your expected cost is explained before treatment begins. Call or text 561-277-8260 to ask about pricing.
NovaGenix is located at 609 North Hepburn Ave, Suite 106, Jupiter, FL 33458. Patients visit from Palm Beach Gardens, Tequesta, Juno Beach, North Palm Beach, Stuart, and Port St. Lucie.
Telehealth is available to eligible patients elsewhere in Florida.
Timothy Mackey, D.O., reviews your health history and medications, discusses whether semaglutide may be appropriate, and monitors treatment throughout.
A physician-directed approach to GLP-1 weight management—built around a real medical evaluation, individualized dosing, and ongoing follow-up.
A consultation does not guarantee a prescription. Eligible Florida patients may be seen by telemedicine.

Clear, medically grounded information before you decide whether a consultation makes sense.
Semaglutide is a GLP-1 receptor agonist and the active ingredient in Wegovy and Ozempic.
Yes. Every NovaGenix patient is evaluated and monitored by Timothy Mackey, D.O.
It is administered as a once-weekly subcutaneous injection with gradual dose increases.
In STEP 1, participants receiving semaglutide plus lifestyle intervention lost 14.9% of starting weight on average at 68 weeks. Results vary.
Eligible patients throughout Florida may be seen by telemedicine when clinically appropriate.
No. Treatment is prescribed only after a medical evaluation confirms it is appropriate.
Semaglutide is the active ingredient in Wegovy and Ozempic. NovaGenix prescribes compounded semaglutide, which is prepared by a licensed compounding pharmacy and is not an FDA-approved finished drug product.
Treatment is prescribed and monitored after a medical evaluation and review of your medications and health history. Semaglutide works by mimicking GLP-1, a naturally occurring hormone involved in appetite regulation.
Eligibility is based on more than a number on the scale. Medical history, current medications, goals, risks, and alternatives all matter.
A physician should review your health history, medications, prior weight-loss treatment, and potential contraindications before any decision is made.
Review important safety information →Semaglutide is a prescription medication—not a program you join by completing an online questionnaire.
Meet with Timothy Mackey, D.O., in Jupiter or by eligible Florida telehealth to review history, medications, and goals.
Laboratory testing is ordered case by case when an underlying thyroid, hormone, or metabolic issue may be relevant.
Treatment starts low and is increased gradually based on tolerability and clinical response.
Follow-up tracks progress, adjusts treatment where appropriate, and addresses side effects early.
Common side effects include nausea, diarrhea, vomiting, constipation, and abdominal discomfort. They are most likely during the first weeks of treatment and while the dose is being increased.
Anything severe or persistent should be reported promptly rather than waiting for the next scheduled visit.
Both are once-weekly injectable medications used for weight management, but they act on different pathways.
Questions often go beyond the medications that are currently available. For a separate educational overview, read what patients should know about retatrutide.
Acts on the GLP-1 receptor. The appropriate medication depends on medical history, other medications, tolerability, cost, and availability.
Acts on both GLP-1 and GIP receptors. The choice is made during consultation—not before your medical evaluation.
Learn about tirzepatide →NovaGenix is a self-pay practice and does not bill insurance. There is no single program price because formulations, strengths, testing, and follow-up needs vary.
Your expected cost is explained before treatment begins. Call or text 561-277-8260.
NovaGenix is located at 609 North Hepburn Ave, Suite 106, Jupiter, FL 33458. Patients visit from Palm Beach Gardens, Tequesta, Juno Beach, North Palm Beach, Stuart, and Port St. Lucie.
Telehealth is available to eligible patients elsewhere in Florida.
Timothy Mackey, D.O., reviews your health history and medications, discusses whether semaglutide may be appropriate, and monitors treatment throughout.
Medically reviewed by Timothy W. Mackey, D.O., Medical Director, NovaGenix. Last reviewed: August 31, 2026.
Semaglutide is the active ingredient in Wegovy and Ozempic. NovaGenix prescribes compounded semaglutide, which is prepared by a licensed compounding pharmacy and is not an FDA-approved product. Your treatment is prescribed and monitored by Timothy W. Mackey, D.O., after a medical evaluation and a review of your medications and health history.

Semaglutide is generally considered for:
If you think you might be a good candidate for semaglutide, it’s important to speak with a doctor. They will be able to help you determine if this medication is right for you, or if you’re a better candidate for a different weight loss treatment.
In the STEP 1 clinical trial, adults with overweight or obesity who did not have diabetes and received semaglutide 2.4 mg once weekly along with lifestyle intervention lost an average of 14.9% of their starting body weight over 68 weeks, compared with 2.4% among participants receiving placebo and lifestyle intervention. Individual results vary.
Semaglutide has been shown to be particularly effective when used in conjunction with a reduced calorie diet plan, as well as some form of exercise. Our doctor will work with you to put together a weight loss plan tailored to your needs.
Semaglutide works by mimicking GLP-1 hormones. GLP (Glucagon-like peptide) is a naturally occurring hormone that targets the appetite-regulating areas of the brain.
When prescribing semaglutide, we slowly increase dosage over the course of 16-20 weeks until the patient can tolerate 2.4 mg per week. This reduces potential side effects. While losing weight slowly can be frustrating for some patients, it is typically much safer and more effective than fast-paced fad diets.
Semaglutide is a prescription medication, not a program you sign up for online. At NovaGenix it is prescribed only after a physician evaluation, and it is monitored while you are on it. Here is what that actually looks like.
1. Your evaluation with Dr. Mackey. Every patient is seen by Timothy W. Mackey, D.O. — not a nurse practitioner or physician assistant. He reviews your medical history, the medications you currently take, and any existing health conditions that bear on whether semaglutide is appropriate for you. Consultations take place at the Jupiter office, or by telehealth if you are an eligible patient in Florida. NovaGenix does not prescribe weight-loss medication on the basis of an online form.
2. Laboratory testing when it is needed. Labs are decided case by case rather than ordered automatically. They are most useful when an underlying cause may be contributing to your weight — a thyroid or hormone disorder, for example — and Dr. Mackey will tell you whether testing is warranted in your case.
3. Ongoing monitoring. Semaglutide is started low and increased gradually, so the first few months involve regular check-ins. Follow-up visits track your progress, adjust dosing where appropriate, and manage side effects as they arise. If the medication is not working for you, or is not tolerable, that is a conversation to have early rather than at the end.
4. Protecting muscle while you lose weight. Rapid weight loss costs lean muscle as well as fat, and that affects both how you feel and how well you keep the weight off. Protein intake, resistance training and hydration all bear on it, and it belongs in the conversation from the start rather than as an afterthought. We covered this in more depth here: protecting muscle during GLP-1 weight loss
Semaglutide is a prescription medication with real risks. The most common side effects are nausea, diarrhea, vomiting, constipation and abdominal discomfort. These are most likely during the first weeks of treatment and while the dose is being increased, which is part of why the dose is raised slowly. More serious risks are possible, and Dr. Mackey reviews the full prescribing information with you before you start.
Side effects vary from person to person. Some patients have none, others have several, and anything severe or persistent is worth reporting to your physician promptly rather than waiting for your next scheduled visit.
Semaglutide and tirzepatide are not appropriate for everyone. These medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or a known serious hypersensitivity to the medication or its ingredients.
These medications also carry important warnings and precautions. Before treatment, patients should tell their healthcare provider about any history of pancreatitis, gallbladder disease, kidney problems, severe gastrointestinal disease or gastroparesis, diabetes or diabetic retinopathy, or previous serious reactions to GLP-1–based medications. Patients taking insulin or certain other diabetes medications may have an increased risk of hypoglycemia.
Semaglutide and tirzepatide used for weight management should be discontinued if pregnancy occurs. Patients who are pregnant, planning pregnancy, or breastfeeding should discuss this with their healthcare provider before treatment.
A medical evaluation and review of medications and health history are necessary to determine whether treatment is appropriate for an individual patient.
Tirzepatide acts on two receptors — GLP-1 and GIP — while semaglutide acts on GLP-1 alone. Both are once-weekly subcutaneous injections used for weight management. Which one suits a given patient depends on medical history, other medications, tolerability, cost and availability, and that decision is made at the consultation rather than before it. You can read more about tirzepatide for weight loss in Jupiter
NovaGenix is a self-pay practice and does not bill insurance. That removes the parts of this process patients find worst — no prior authorization to chase, no insurance denial to appeal, no pharmacy back-and-forth — and it also means the cost of treatment is paid directly.
There is no single program price, because patients need different formulations, strengths, laboratory testing and follow-up. What you pay depends on what Dr. Mackey recommends after your evaluation, and your expected cost is explained in full before you begin treatment. Call or text 561-277-8260 to ask about pricing for your situation.
NovaGenix is located at 609 North Hepburn Ave, Suite 106, Jupiter, FL 33458. Patients travel to the Jupiter office from Palm Beach Gardens, Tequesta, Juno Beach, North Palm Beach, Stuart and Port St. Lucie. Telehealth consultations are available to eligible patients elsewhere in Florida. Call or text 561-277-8260 to schedule.
Semaglutide is the active ingredient in Wegovy and Ozempic. NovaGenix prescribes compounded semaglutide, which is prepared by a licensed compounding pharmacy and is not an FDA-approved product. Dr. Mackey explains what that means for you at your consultation.
Not always. Laboratory testing is decided case by case, based on your history and the treatment being considered. What does not vary is the evaluation itself: NovaGenix does not prescribe weight-loss medication on the basis of an online form.
Consultations may be conducted in person at the Jupiter office or by telehealth, depending on what is clinically appropriate for your situation. Telehealth is available to eligible patients in Florida. A consultation is required either way, and it does not guarantee that a medication will be prescribed.
Weight regain can occur after treatment stops. Planning for that is part of treatment rather than something addressed at the end — nutrition, activity, sleep, other medical conditions, and whether continued medication is appropriate are all part of the conversation before you finish.
Every patient at NovaGenix is seen by Timothy W. Mackey, D.O. — not a nurse practitioner or physician assistant. He reviews your health history and medications, discusses whether semaglutide is appropriate for you, and monitors your treatment throughout. Call or text 561-277-8260 to schedule a consultation in Jupiter.

Learn what you want to know about hormone therapy by scheduling a free consultation.
Contact Us Today609 N Hepburn Ave Ste 106, Jupiter, FL 33458
Monday - Friday: 9:00 am - 5:00 pm | Saturday-Sunday: Closed